glp 1 stomach paralysis risk may rise in people taking Ozempic and similar drugs Do GLP-1s cause "stomach paralysis"?

In November 2023, the FDA granted approval for tirzepatide under the brand name Zepbound for chronic weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with at least one weight-related comorbidity, as an adjunct to a reduced-calorie diet and increased physical activity

Oral GLP-1 currently represented by Rybelsus (oral semaglutide 7mg/14mg daily) for T2DM and advanced by Eli Lilly's orforglipron in late-stage trials is growing at the fastest route of administration CAGR because it fundamentally removes the injection barrier that constrains GLP-1 therapy adoption in the substantial patient population for whom daily or weekly self-injection is a genuine disincentive to treatment initiation or maintenance

Tirzepatide GLP-1s may also reduce the risk of mortality by 62% in people with type 2 diabetes who undergo a percutaneous coronary intervention (PCI) procedure compared with those taking dulaglutide

Insulin signaling pathway and related molecules: Role in neurodegeneration and alzheimers disease

The Appeal Playbook If you are technically insured but were denied, the denial type decides whether appealing is worth it, and most people never file

Annual Review of Medicine, 56, 443458